Quture/TCLN Announces Formation of Subsidiary for European Operations
May 14 2012 - 8:00AM
Marketwired
Quture International, Inc. (PINKSHEETS: TCLN) (OTCQB: TCLN) and its operations
subsidiary
Quture, Inc. ("Quture") announce
the formation of a second subsidiary of Quture International, filed
as Quture Euro, LLC, a Florida limited liability company. The
Company is currently negotiating to conduct a proof of concept for
its QualOptima product in hospitals in Portugal. These endeavors
follow introductions of Richard Fantozzi, M.D., by InterSystems
Iberia during his April participation at the beginning of their
European and international campaigns for its QualOptima product at
the Future Health Congress in Lisbon, Portugal
(www.futurehealthmeeting.net). Quture International is aggressively
implementing its business and strategic plans with formation of
this second subsidiary signaling the beginning of the marketing and
sales campaign in Europe for its products and services.
"The focus of Quture products in Europe will be slightly
different because of the needs of hospitals and physicians," said
Richard Fantozzi, M.D., CEO and Co-Chairman of Quture, Inc. "I am
impressed with the keen interest and desire from hospitals in
Portugal to work with Quture based on their needs and the
advantages of QualOptima. It is a genuine professional pleasure to
work alongside InterSystems sales and software engineers in Europe,
with their strong customer base and extraordinary reputation of
products and customer relations."
Formation of Quture Euro is an integral strategy of the Quture
Management Team to align their respective skills, roles, and
responsibilities within Quture International. A separate operations
subsidiary in Europe is a key component of the global plan and
competency of the Company.
"We are moving decisively to take advantage of the strength of
our partner InterSystems in Europe. A subsidiary focused on Europe
provides the Company with a significant array of business
strategies and opportunities that are potentially of enormous
valuable," said Landon Feazell, Chairman & CEO of Quture
International, Inc. "This is consistent with the plans of the
Company to become the international standard in healthcare
performance and outcomes measurement. Performance analytics is
truly the international solution to improve care and reduce costs.
It is not just an American solution, it is the global solution. We
believe our QualOptima product will be a major force in the
transformation of healthcare payment and delivery systems."
QUTURE INTERNATIONAL, INC. Quture
International, Inc. is an emerging growth company positioned to
become the leading clinical knowledge company in the world. The
core competence of Quture is clinical performance enhancement to
achieve optimal patient outcomes. Quture's brand is centered on the
value proposition of trust, transparency and independence. As the
free enterprise solution to improving health and health care while
reducing costs, Quture is comprised of a subsidiaries in North
America and Europe for the operations of its software technology
solutions, plans for a "beyond data" consulting and knowledge
applications company, as well as plans for a personalized,
proactive, and predictive medicine company with a virtual community
of members. These subsidiaries will all be affiliated with the Qx
Medical Exchange, which the Company intends to become the largest
medical and health exchange in the world. Quture International is a
Nevada corporation currently trading under the symbol TCLN.
QUTURE, INC. Quture, Inc. is the
operations subsidiary of Quture International, Inc., positioned to
become the international standard in health care performance,
outcomes and analytics. Quture's transformational product
QualOptima operates on the InterSystems technology platform, the
leading software platform globally for health care. QualOptima is
the transcendent healthcare analytics system for performance
enhancement to achieve optimal patient outcomes. The analytics
system measures performance against evidence-based optimal clinical
processes of care. The clinical data repository of QualOptima, the
Qualytx integrated aggregate clinical database, is planned to
become the international common data platform for health and health
care. Qualytx will then be capable of transforming personal health
and health care through knowledge solutions founded on Quture's
proprietary science of knowing what to measure, where that data
resides in disparate databases, using the InterSystems technology
to electronically abstract that data, and converting data to
knowledge and actionable insight with its revolutionary and
proprietary analytics system. As America transitions to payment for
value and U.S. and international pressures converge to measure
performance, Quture will navigate the future of global health and
healthcare quality, patient safety and value.
This release contains forward-looking statements, including,
without limitation, statements concerning our business and possible
or assumed future results of operations. Our actual results could
differ materially from those anticipated in the forward-looking
statements for many reasons including: our ability to continue as a
going concern, adverse economic changes affecting markets we serve;
competition in our markets and industry segments; our timing and
the profitability of entering new markets; greater than expected
costs, customer acceptance of our products or difficulties related
to our integration of the businesses we may acquire; and other
risks and uncertainties as may be detailed from time to time in our
public announcements and SEC filings. Although we believe the
expectations reflected in the forward-looking statements are
reasonable, they relate only to events as of the date on which the
statements are made, and our future results, levels of activity,
performance or achievements may not meet these expectations. We do
not intend to update any of the forward-looking statements after
the date of this document to conform these statements to actual
results or to changes in our expectations, except as required by
law. There is no assurance that a definitive agreement will be
completed.
For Further Information Contact: Constellation Asset
Advisors, Inc. Jens Dalsgaard President +1 (415) 524-8500
Contact: Mele Telitz Director of Communications 303-204-4486
mele@quture.com